Five Years On: UK Reviews Transposition Of EU Pharmacovigilance Directive, Other Changes
The UK medicines regulator is undertaking a post-implementation review of the Human Medicines Regulations 2012, which introduced significant changes for the medicines sector such as national requirements in relation to the EU pharmacovigilance directive.
You may also be interested in...
The Human Medicines Regulations 2012 has entered into force in the UK, consolidating and simplifying over 40 years of the country's drugs legislation in such a way as to reduce regulatory burden on businesses1,2.
The UK’s deployment of COVID-19 vaccines has left vaccine manufacturers worried about emerging discussions on dosing strategies that may not be supported by authorized labeling or published clinical data.
Existing importers and manufacturers of certain medical devices can continue marketing their products for six months or until the Indian medtech regulator makes a final decision on their pending licensing applications.